Interview: Simplifying Existing Procedure Eases Market Penetration for Photocure

Published: 7 October 2012

President and CEO Kjetil Hestdal discusses the company's photodynamic technology harnessed in Hexvix® and Allumera®. Hexvix®, branded as Cysview® in the U.S., aids in cystoscopy procedures for bladder cancer.

Photocure already has a market penetration of 30% in the Nordic region, says Hestdal, and hopes to replicate that in the 230,000 procedures performed annually in the United States. He discusses the company’s dermatological product Allumera® and details research on Phase II acne treatment Visonac®, which he says has shown good efficacy and comparable results to existing oral antibiotics, though without some of the negatives:
Interview with Kjetil Hestdal

The conversation includes development expectations for 2013 and 2014 and partnership details for the company, as well as the company’s capital structure.

News and events

Key InformationProviding an update on the XYZ incident

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do